Oncotelic Therapeutics Inc. (OTCQB: OTLC) is making a significant push in the artificial intelligence-driven drug discovery space with the integration of approximately 28 million scientific abstracts into its proprietary PDAOAI platform. The move, announced by the California-based oncology company, marks a milestone in its efforts to leverage AI as a core infrastructure for drug development, rather than merely a research accelerator.
The global AI in drug-discovery market, valued at roughly $3.25 billion in 2026, is projected to grow at a compound annual growth rate of about 26% through 2031, reaching over $10 billion, according to industry reports. This context highlights the strategic importance of Oncotelic's platform, which is designed to process vast amounts of scientific literature to identify novel drug targets and accelerate the development of therapeutics.
Oncotelic's PDAOAI platform, built over several years, is intended to be more than an internal tool. By integrating 28 million abstracts, the company aims to create a comprehensive database that can generate insights across multiple disease areas. This approach could potentially reduce the time and cost associated with traditional drug discovery, which often relies on manual literature review and hypothesis generation.
The company's strategy reflects a broader trend in the life sciences sector, where AI is becoming a defining infrastructure layer. Companies that control the most intelligent platforms may ultimately shape the industry's future, and Oncotelic is positioning itself among these players despite being a smaller biotech compared to big pharma.
For investors, the latest developments are available in the company's newsroom at ibn.fm/OTLC. The integration of such a large dataset into the PDAOAI platform demonstrates Oncotelic's commitment to advancing its AI capabilities and could signal upcoming milestones in its drug development pipeline.
This news comes as part of a broader narrative of AI's transformative potential in healthcare. Oncotelic's ability to out-innovate larger competitors will depend on how effectively it can translate these data-driven insights into viable treatments. The company's focus on oncology, a field with high unmet medical needs, adds to the significance of its platform, as AI-driven approaches may uncover new therapeutic avenues more efficiently than conventional methods.
